1 |
Caldas, C., and Kern, S.E. (1995). K-ras mutation and pancreatic adenocarcinoma. Int. J. Pancreatol. 18, 1-6.
|
2 |
Ayoub, N., Rajendra, E., Su, X., Jeyasekharan, A.D., Mahen, R., and Venkitaraman, A.R. (2009). The carboxyl terminus of Brca2 links the disassembly of Rad51 complexes to mitotic entry. Curr. Biol. 19, 1075-1085.
DOI
ScienceOn
|
3 |
Breast Cancer Linkage Consortium (1999). The breast cancer linkage consortium: cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 91, 1310-1316.
DOI
|
4 |
Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., and Helleday, T. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917.
DOI
ScienceOn
|
5 |
Cancer Genome Atlas Consortium (2011). Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615.
DOI
ScienceOn
|
6 |
Carreira, A., Hilario, J., Amitani, I., Baskin, R.J., Shivji, M.K., Venkitaraman, A.R., and Kowalczykowski, S.C. (2009). The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51. Cell 136, 1032-1043.
DOI
ScienceOn
|
7 |
Friedman, L.S., Thistlethwaite, F.C., Patel, K.J., Yu, V.P., Lee, H., Venkitaraman, A.R., Abel, K.J., Carlton, M.B., Hunter, S.M., Colledge, W.H., et al. (1998). Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res. 58, 1338-1343.
|
8 |
Couch, F.J., Johnson, M.R., Rabe, K.G., Brune, K., de Andrade, M., Goggins, M., Rothenmund, H., Gallinger, S., Klein, A., Petersen, G.M., et al. (2007). The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 16, 342-346.
DOI
ScienceOn
|
9 |
Daniels, M.J., Wang, Y., Lee, M., and Venkitaraman, A.R. (2004). Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306, 876-879.
DOI
ScienceOn
|
10 |
Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights C., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.
DOI
ScienceOn
|
11 |
Gretarsdottir, S., Thorlacius, S., Valgardsdottir, R., Gudlaugsdottir, S., Sigurdsson, S., Steinarsdottir, M., Jonasson, J.G., Anamthawat- Jonsson, K., and Eyfjord, J.E. (1998). BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res. 58, 859-862.
|
12 |
Hahn, S.A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., Gerdes, B., Kress, R., Ziegler, A., Raeburn, J.A., et al. (2003). BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl. Cancer Inst. 95, 214-221.
DOI
ScienceOn
|
13 |
Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., and Depinho, R.A. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249.
DOI
ScienceOn
|
14 |
Jonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M., and Berns, A. (2001). Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418-425.
DOI
ScienceOn
|
15 |
Hruban, R., Pitman, M., and Klimstra, D.S. (2007). Tumors of the Pancreas, AFIP ATLAS of Tumour Pathology, Series IV, (American Registry of Pathology).
|
16 |
Lee, M., Daniels, M.J., Garnett, M.J., and Venkitaraman, A.R. (2011). A mitotic function for the high-mobility group protein HMG20b regulated by its interaction with the BRC repeats of the BRCA2 tumor suppressor. Oncogene 30, 3360-3369.
DOI
ScienceOn
|
17 |
Jeyasekharan, A.D., Liu, Y., Hattori, H., Pisupati, V., Jonsdottir, A.B., Rajendra, E., Lee, M., Sundaramoorthy, E., Schlachter, S., Kaminski, C.F., et al. (2013). A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization. Nat. Struct. Mol. Biol. 20, 1191-1198.
DOI
ScienceOn
|
18 |
King, T.A., Li, W., Brogi, E., Yee, C.J., Gemignani, M.L., Olvera, N., Levine, D.A., Norton, L., Robson, M.E., Offit, K., et al. (2007). Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann. Surg. Oncol. 14, 2510-2518.
DOI
|
19 |
Lomonosov, M., Anand, S., Sangrithi, M., Davies, R., and Venkitaraman, A.R. (2003). Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev. 17, 3017-3022.
DOI
ScienceOn
|
20 |
Maitra, A., and Hruban, R.H. (2008). Pancreatic cancer. Annu. Rev. Pathol. 3, 157-188.
DOI
ScienceOn
|
21 |
Menzel, T., Nahse-Kumpf, V., Kousholt, A.N., Klein, D.K., Lund-Andersen, C., Lees, M., Johansen, J.V., Syljuasen, R.G., and Sorensen, C.S. (2011). A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance. EMBO Rep. 12, 705-712.
DOI
ScienceOn
|
22 |
Parkin, D.M., Bray, F.I., and Devesa, S.S. (2001). Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4-66.
|
23 |
Mikaelsdottir, E.K., Valgeirsdottir, S., Eyfjord, J.E., and Rafnar, T. (2004). The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res. 6, R284-290.
DOI
ScienceOn
|
24 |
Redston, M.S., Caldas, C., Seymour, A.B., Hruban, R.H., da Costa, L., Yeo, C.J., and Kern, S.E. (1994). p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 54, 3025-3033.
|
25 |
Mondal, G., Rowley, M., Guidugli, L., Wu, J., Pankratz, V.S., and Couch, F.J. (2012). BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis. Dev. Cell 23, 137-152.
DOI
ScienceOn
|
26 |
Patel, K.J., Yu, V.P., Lee, H., Corcoran, A., Thistlethwaite, F.C., Evans, M.J., Colledge, W.H., Friedman, L.S., Ponder, B.A., and Venkitaraman, A.R. (1998). Involvement of Brca2 in DNA repair. Mol. Cell 1, 347-357.
DOI
ScienceOn
|
27 |
Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., and Jasin, M. (2011). Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 145, 529-542.
DOI
ScienceOn
|
28 |
Shivji, M.K., Mukund, S.R., Rajendra, E., Chen, S., Short, J.M., Savill, J., Klenerman, D., and Venkitaraman, A.R. (2009). The BRC repeats of human BRCA2 differentially regulate RAD51 binding on single- versus double-stranded DNA to stimulate strand exchange. Proc. Natl. Acad. Sci. USA 106, 13254-13259.
DOI
ScienceOn
|
29 |
Thompson, D., and Easton, D.F. (2002). Cancer incidence in BRCA1 mutation carriers. J. Natl. Cancer Inst. 94, 1358-1365.
DOI
ScienceOn
|
30 |
Skoulidis, F., Cassidy, L.D., Pisupati, V., Jonasson, J.G., Bjarnason, H., Eyfjord, J.E., Karreth, F.A., Lim, M., Barber, L.M., Clatworthy, S.A., et al. (2010). Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 18, 499-509.
DOI
ScienceOn
|
31 |
Venkitaraman, A.R. (2009). Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu. Rev. Pathol. 4, 461-487.
DOI
ScienceOn
|
32 |
Tirkkonen, M., Johannsson, O., Agnarsson, B.A., Olsson, H., Ingvarsson, S., Karhu, R., Tanner, M., Isola, J., Barkardottir, R.B., Borg, A., et al. (1997). Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 57, 1222-1227.
|
33 |
Tutt, A.N., van Oostrom, C.T., Ross, G.M., van Steeg, H., and Ashworth, A. (2002). Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation. EMBO Rep. 3, 255-260.
DOI
ScienceOn
|
34 |
Venkitaraman, A.R. (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171-182.
DOI
ScienceOn
|
35 |
West, S.C. (2003). Molecular views of recombination proteins and their control. Nat. Rev. Mol. Cell Biol. 4, 435-445.
|
36 |
Willems-Jones, A., Kavanagh, L., Clouston, D., Bolton, D., kCon-Fab Investigators, Fox, S., and Thorne, H. (2012). High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer. BJU Int. 110, E1181-E1186.
DOI
ScienceOn
|
37 |
Wooster, R., Neuhausen, S.L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D., et al. (1994). Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265, 2088-2090.
DOI
|
38 |
Xu, X., Weaver, Z., Linke, S.P., Li, C., Gotay, J., Wang, X.W., Harris, C.C., Ried, T., and Deng, C.X. (1999). Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3, 389-395.
DOI
ScienceOn
|
39 |
Yu, V.P., Koehler, M., Steinlein, C., Schmid, M., Hanakahi, L.A., van Gool, A.J., West, S.C., and Venkitaraman, A.R. (2000). Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev. 14, 1400-1406.
|
40 |
Choi, E., Park, P.G., Lee, H.O., Lee, Y.K., Kang, G.H., Lee, J.W., Han, W., Lee, H.C., Noh, D.Y., Lekomtsev, S., et al. (2012). BRCA2 fine-tunes the spindle assembly checkpoint through reinforcement of BubR1 acetylation. Dev. Cell 22, 295-308
DOI
ScienceOn
|